Author:
Adami Silvano,Bianchi Gerolamo,Brandi Maria Luisa,Giannini Sandro,Ortolani Sergio,DiMunno Ombretta,Frediani Bruno,Rossini Maurizio,
Publisher
Springer Science and Business Media LLC
Subject
Endocrinology,Orthopedics and Sports Medicine,Endocrinology, Diabetes and Metabolism
Reference27 articles.
1. EMEA–CHMP (2007) Guidelines on the evaluation of new medicinal products in the treatment of primary osteoporosis. http://www.emea.europa.eu/pdfs/human/ewp/055295en.pdf . Accessed 7 September 2007
2. Melton LJ III, Atkinson EJ, O’Fallon WM, Wahner HW, Riggs BL (1993) Long-term fracture prediction by bone mineral assessed at different skeletal sites. J Bone Miner Res 8:1227–1233
3. Riis BJ, Hansen MA, Jensen AM, Overgaard K, Christiansen C (1996) Low bone mass and fast rate of bone loss at menopause: equal risk factors for future fracture: a 15-year follow-up study. Bone 19:9–12
4. Garnero P (2000) Markers of bone turnover for the prediction of fracture risk. Osteoporos Int 11 Suppl 6:S55–S65
5. Bjarnason NH, Sarkar S, Duong T, Mitlak B, Delmas PD, Christiansen C (2001) Six and twelve month changes in bone turnover are related to reduction in vertebral fracture risk during 3 years of raloxifene treatment in postmenopausal osteoporosis. Osteoporos Int 12:922–930
Cited by
99 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献